Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

Steven E Lipshultz, Sarah A. Vlach, Stuart R. Lipsitz, Stephen E. Sallan, Marcy L. Schwartz, Steven D. Colan

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.

Original languageEnglish
Pages (from-to)1613-1622
Number of pages10
JournalPediatrics
Volume115
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Anthracyclines
Growth Hormone
Therapeutics
Survivors
Control Groups
Neoplasms
Left Ventricular Dysfunction

Keywords

  • Anthracyclines
  • Cardiac changes
  • Cardiomyopathy
  • Congestive heart failure
  • Growth hormone
  • Pediatric cancer

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Lipshultz, S. E., Vlach, S. A., Lipsitz, S. R., Sallan, S. E., Schwartz, M. L., & Colan, S. D. (2005). Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics, 115(6), 1613-1622. https://doi.org/10.1542/peds.2004-1004

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. / Lipshultz, Steven E; Vlach, Sarah A.; Lipsitz, Stuart R.; Sallan, Stephen E.; Schwartz, Marcy L.; Colan, Steven D.

In: Pediatrics, Vol. 115, No. 6, 01.06.2005, p. 1613-1622.

Research output: Contribution to journalArticle

Lipshultz, SE, Vlach, SA, Lipsitz, SR, Sallan, SE, Schwartz, ML & Colan, SD 2005, 'Cardiac changes associated with growth hormone therapy among children treated with anthracyclines', Pediatrics, vol. 115, no. 6, pp. 1613-1622. https://doi.org/10.1542/peds.2004-1004
Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics. 2005 Jun 1;115(6):1613-1622. https://doi.org/10.1542/peds.2004-1004
Lipshultz, Steven E ; Vlach, Sarah A. ; Lipsitz, Stuart R. ; Sallan, Stephen E. ; Schwartz, Marcy L. ; Colan, Steven D. / Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. In: Pediatrics. 2005 ; Vol. 115, No. 6. pp. 1613-1622.
@article{ed95c49a051c4fb1b786c94900aacbf2,
title = "Cardiac changes associated with growth hormone therapy among children treated with anthracyclines",
abstract = "Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.",
keywords = "Anthracyclines, Cardiac changes, Cardiomyopathy, Congestive heart failure, Growth hormone, Pediatric cancer",
author = "Lipshultz, {Steven E} and Vlach, {Sarah A.} and Lipsitz, {Stuart R.} and Sallan, {Stephen E.} and Schwartz, {Marcy L.} and Colan, {Steven D.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1542/peds.2004-1004",
language = "English",
volume = "115",
pages = "1613--1622",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

AU - Lipshultz, Steven E

AU - Vlach, Sarah A.

AU - Lipsitz, Stuart R.

AU - Sallan, Stephen E.

AU - Schwartz, Marcy L.

AU - Colan, Steven D.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.

AB - Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.

KW - Anthracyclines

KW - Cardiac changes

KW - Cardiomyopathy

KW - Congestive heart failure

KW - Growth hormone

KW - Pediatric cancer

UR - http://www.scopus.com/inward/record.url?scp=22544462786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544462786&partnerID=8YFLogxK

U2 - 10.1542/peds.2004-1004

DO - 10.1542/peds.2004-1004

M3 - Article

VL - 115

SP - 1613

EP - 1622

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -